TherapeuticsMD (TXMD) Cash & Current Investments (2010 - 2026)

TherapeuticsMD (TXMD) has reported Cash & Current Investments for 17 consecutive years, with $9.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments rose 51.41% year-over-year to $9.2 million; the trailing twelve-month figure through Jun 2026 stood at $9.2 million (up 51.41% YoY), and the FY2025 full-year result was $7.5 million, up 47.91% from the prior year.
• Cash & Current Investments grew to $9.2 million in Q2 2026 per TXMD's latest filing, from $8.4 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $60.6 million in Q4 2022 and bottomed at $4.3 million in Q4 2023.
• Historically, Cash & Current Investments has averaged $16.6 million across 5 years, with a median of $8.0 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Cash & Current Investments plunged 92.86% in 2023, then surged 51.41% in 2026.
• Over 5 years, Cash & Current Investments stood at $60.6 million in 2022, then slumped by 92.86% to $4.3 million in 2023, then climbed by 16.92% to $5.1 million in 2024, then jumped by 47.91% to $7.5 million in 2025, then grew by 22.8% to $9.2 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $9.2 million, $8.4 million, and $7.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.